- Home
- AXS vs ABVX Comparison
AXS vs ABVX Comparison
Compare AXS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | AXS | ABVX |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | Bermuda | France |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AXS | ABVX |
|---|---|---|
| Price | $108.61 | $142.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $117.00 | $115.83 |
| AVG Volume (30 Days) | 582.9K | ★ 1.8M |
| Earning Date | 01-28-2026 | 08-11-2025 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | ★ 68.27 | N/A |
| EPS | ★ 12.10 | N/A |
| Revenue | ★ $6,301,015,000.00 | $6,231,374.00 |
| Revenue This Year | $6.62 | $6.80 |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $9.01 | ★ N/A |
| Revenue Growth | ★ 5.59 | N/A |
| 52 Week Low | $83.90 | $4.77 |
| 52 Week High | $110.34 | $148.83 |
Technical Indicators
Market Signals| Indicator | AXS | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 72.43 | 65.24 |
| Support Level | $105.67 | $108.53 |
| Resistance Level | $110.34 | $148.83 |
| Average True Range (ATR) | 1.77 | 7.47 |
| MACD | 0.42 | 2.18 |
| Stochastic Oscillator | 87.38 | 84.29 |
Price Performance
Historical ComparisonAbout AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States ("U.S."), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of AXIS Insurance and AXIS Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.